The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

P. Treon, Steven; J. Castillo, Jorge; P Skarbnik, Alan; D. Soumerai, Jacob; M. Ghobrial, Irene; Luisa Guerrera, Maria; Meid, Kirsten; Yang, Guang

doi:10.1182/blood.2020006288

Public

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Published in Blood • Apr 17, 2020

Authors:

Steven P. Treon

Jorge J. Castillo

Alan P Skarbnik

Abstract

Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.

Subject

Ibrutinib

Bruton's tyrosine kinase

Coronavirus disease 2019 (COVID-19)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!